Home » Stocks » ENZ

Enzo Biochem, Inc. (ENZ)

Stock Price: $2.92 USD -0.03 (-1.02%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 139.85M
Revenue (ttm) 84.47M
Net Income (ttm) -20.57M
Shares Out 47.90M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.92
Previous Close $2.95
Change ($) -0.03
Change (%) -1.02%
Day's Open 2.95
Day's Range 2.86 - 3.21
Day's Volume 240,741
52-Week Range 1.56 - 4.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U...

GlobeNewsWire - 1 month ago

NEW YORK, NY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of D...

PRNewsWire - 1 month ago

CHEVY CHASE, Md., Jan. 5, 2021 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock (the "Common Stock") of Enzo Biochem, Inc. ...

GlobeNewsWire - 1 month ago

- Use of pooled sampling with Enzo's molecular diagnostic technology can help rapidly expand the number of people tested for COVID-19 -

PRNewsWire - 1 month ago

CHEVY CHASE, Md., Dec. 31, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" ...

GlobeNewsWire - 2 months ago

NEW YORK, NY, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the...

PRNewsWire - 2 months ago

CHEVY CHASE, Md., Dec. 24, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc.(NYSE: ENZ) ("Enzo" o...

Seeking Alpha - 2 months ago

Enzo Biochem, Inc. has continued to underperform its peers and the general markets despite the tailwind from the pandemic outbreak. In November 2020, two investment funds went activist on the ...

GlobeNewsWire - 2 months ago

Thursday, December 17th @ 12:00pmET

Seeking Alpha - 2 months ago

Enzo Biochem, Inc. (ENZ) Q1 2021 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Conference call and live webcast scheduled for today, Wednesday , December 9 , 2020 at 4:30 pm (ET)

GlobeNewsWire - 2 months ago

Conference Call and Webcast Scheduled for December 9, 2020, 4:30 pm ET

GlobeNewsWire - 3 months ago

NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD,...

GlobeNewsWire - 3 months ago

NEW YORK, NY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, M...

GlobeNewsWire - 4 months ago

Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing and will expand to include other testing in the future

Seeking Alpha - 4 months ago

Enzo Biochem, Inc.'s (ENZ) on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

Conference call and live webcast scheduled for today, Tuesday, October 13, 2020 at 4:30 pm (ET)

GlobeNewsWire - 4 months ago

Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET

Seeking Alpha - 5 months ago

Enzo Biochem, Inc: Wildly Undervalued COVID-19 Test Play With Near-Term Catalysts

GlobeNewsWire - 7 months ago

New initiative introduces Enzo’s Independent Pharmacy Testing Program with full range of products and services to support rapid and accurate testing to more residents of New York State New ini...

Market Watch - 7 months ago

Shares of Enzo Biochem Inc. ENZ, +6.71% rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for ...

GlobeNewsWire - 7 months ago

Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIP...

GlobeNewsWire - 7 months ago

First Collaboration under Enzo’s School and Institution Testing (“SIT”) Program

GlobeNewsWire - 8 months ago

Continues to Explore Opportunities for Use of the Compound as a Potential Treatment for COVID-19

Seeking Alpha - 8 months ago

Enzo Biochem, Inc. (ENZ) Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

GlobeNewsWire - 9 months ago

Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program

GlobeNewsWire - 9 months ago

NEW YORK, NY, April 29, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.  (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624...

Benzinga - 10 months ago

Enzo Biochem, Inc. (NYSE: ENZ) shares were rallying Thursday following an update from the company on its comprehensive COVID-19 program.

Benzinga - 11 months ago

The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagn...

Other stocks mentioned: NNVC, OPK, SPEX
Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) Management on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) President Barry Weiner on Q3 2019 Results - Earnings Call Transcript

About ENZ

Enzo Biochem, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and... [Read more...]

Industry
Diagnostics & Research
Founded
1976
CEO
Elazar Rabbani
Employees
408
Stock Exchange
NYSE
Ticker Symbol
ENZ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Enzo Biochem is 5.50, which is an increase of 88.36% from the latest price.

Price Target
$5.50
(88.36% upside)